Per Editor: Yang Huan
Chengdu Tianfu International Bio-City Image source: Courtesy of Chengdu High-tech Zone
On December 16th, the first International Summit Forum on the Innovative Development of New Drugs of Anzhes Biologics and the opening ceremony of Anzhes Biology were held in Chengdu Tianfu International Bio-City, and Chengdu Anzhes Biomedical Technology Co., Ltd. (hereinafter referred to as Anzhes) officially settled in Chengdu Tianfu International Bio-City. After settling in, Angels will build an innovative drug research and development exchange platform to promote more Chinese local innovative drugs from the bio-city to the world.
At the event, Chengdu Tianfu International Bio-City awarded licenses to the first batch of 11 public technical service platforms. These 11 platforms will provide enterprises in the park with services covering drug screening, large animal experiments, inspection and testing, drug safety assessment, project incubation, cell therapy, biomaterials, supply chain, reagents and other subdivisions to achieve professional resource sharing.
Established in July this year, Angels is the head office of the NJS Associates Company in China. It is understood that NJS, with clinical trial statistics and medical experts as the core team, is a global CRO company, and since its inception, it has successfully helped more than 20 of the world's top pharmaceutical companies to pass the FDA/EMA new drug approval. According to the relevant person in charge of Anzhes, the company will take the experience of international new drug development as the core competitiveness, make full use of the strategic partnership with experts in various fields, take global pharmaceutical research and development as the vision, clearly position the global clinical research and development strategy of local innovative drugs, and provide one-stop clinical trial outsourcing services covering program design, project management, clinical operation, medical support, approval, data management and statistical analysis with Sino-US dual reporting as the short-term goal, so as to promote more Chinese local innovative drugs to the world.
Chengdu Tianfu International Bio-City is jointly built by Chengdu High-tech Zone and Shuangliu District. Up to now, it has signed 170 projects, gathered 27 innovative public service platforms, and introduced and cultivated 134 new drug varieties, with a total investment of more than 110 billion yuan. In the high-quality science and technology innovation space that has been presented, four listed enterprises such as Chengdu Pilot have been born.
Daily economic news
![Ziwei deep happiness course said childhood[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)